ClinicalTrials.Veeva

Menu

Preeclampsia and Defective Placentation in Oocyte Donation: Importance of HLA-C and KIR (IMMUN-OR)

U

Universitair Ziekenhuis Brussel

Status

Not yet enrolling

Conditions

Preeclampsia (PE) Risk
Oocyte Donation

Study type

Observational

Funder types

Other

Identifiers

NCT07178652
EC 2023-228

Details and patient eligibility

About

The IMMUN-OR study aims to study HLA-C/KIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation. With the use of oocyte donation currently on the rise, the importance of identifying risk factors for the higher frequency of PE development is clear. Certain HLA-C/KIR combinations have already been linked to higher risk of obstetric complications. This study will look at these combinations within the specific situation of oocyte donation. This will further investigate the importance of the immunological interface when looking at PE. Participants will be chosen from a database of all the live births after oocyte donation at our center. The research team will contact the mother, child and donor. If all three agree to participate, they will be invited to our center, where the research team will take a cheek swab. This swab will then be used to isolate a DNA sample. With these samples, we can determine the HLA-C/KIR combination for each threesome. When all samples have been collected, two groups are made based off their health outcome: one group that did develop PE during their pregnancy, and one group that did not develop PE. The different HLA-C/KIR combinations will be compared, and the research team will look to discover if one combination is linked to a higher occurrence of PE development.

Enrollment

2,325 estimated patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Every live birth delivery post oocyte donation (mother, child, donor).

Exclusion criteria

  • Unknown HLA-C/KIR typing of acceptor, donor or offspring (resumlts of all 3 parties must be present to participate.

Trial design

2,325 participants in 2 patient groups

PE
Description:
Patients who develop PE during their pregnancy after oocyte donation.
No PE
Description:
Patients who do not develop PE during their pregnancy after oocyte donation.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems